U lcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory conditions of the gut and comprise the main types of inflammatory bowel disease (IBD). The main signs and symptoms of both UC and CD are observed in the digestive tract. However, manifestations of these disorders are not locally restricted to the intestine, and a significant portion of IBD patients, ranging between 12% and 35% in UC and between 25% and 70% in CD, show concomitant associated extraintestinal manifestations (EIMs). [1] [2] [3] [4] There is a broad range of EIMs such as musculoskeletal, metabolic bone disease, mucocutaneous, ocular, hepatobiliary, vascular, or hematologic. The most prevalent EIMs in IBD are arthritis (range, 7.2%-28.6% of IBD patients), osteoporosis (11%-14.8%), uveitis (2.1%-5.3%), erythema nodosum (1.7%-5.1%), psoriasis (1.5%-2.5%), ankylosing spondylitis (1.4%-4.1%), sacroilitis (1.9%-4.9%), oral aphthous stomatitis (0.7%-7.4%), pyoderma gangrenosum (0.6%-1.8%), and primary sclerosing cholangitis (0.4%-1.8%). [1] [2] [3] [4] [5] [6] [7] [8] Although the majority of IBD patients usually have 1 EIM at a time, there are reports of as many as 25% of patients experiencing several EIMs at the same time. 2 The scientific community is showing growing interest in better understanding the incidence and management of EIMs in IBD in general [9] [10] [11] because of their strong impact on patient's quality of life. 12, 13 Very recently, consensus recommendations on the management of EIMs in IBD patients have been published by the European Crohn's and Colitis Organisation (ECCO).
14 ECCO recommends considering tumor necrosis factor (TNF) antagonists (ie, infliximab or adalimumab) as possible alternatives for the management of UC and CD patients presenting with spondyloarthropathy, arthritis, mucocutaneous manifestations such as pyoderma gangrenosum or erythema nodosum, and in patients with scleritis or uveitis, and some potential benefit of anti-TNF treatment in patients with metabolic bone disease or coagulopathy is described. 14 Many EIMs (eg, arthritis, erythema nodosum, pyoderma gangrenosum, iritis, uveitis) share a pathogenic TNF-a dependent mechanism with IBD. The introduction of new biologic therapies for the management of IBD, particularly anti-TNF drugs, is perceived as an opportunity to improve the outcomes of EIMs in these patients 15 ; however, little is known about the efficacy and effectiveness of these new therapies in the management of EIMs.
Several literature reviews have been published in the last few years trying to summarize the evidence available on the use of biologic drugs for the management of EIMs in IBD. [16] [17] [18] The authors of these studies concluded that anti-TNF therapy should be considered in patients with EIMs because of beneficial effect observed. However, none of these reviews have been conducted through a systematic approach. This is a systematic review aimed at assessing previously published interventional and non-interventional studies that investigate the efficacy and the effectiveness, respectively, of biologic drugs in the treatment of EIMs in IBD.
Methods
The scope of the systematic review was defined in a protocol that guided the development of search strategy, study selection, data extraction, and reporting.
Search Strategy
Two systematic literature searches to identify relevant citations for interventional and non-interventional studies were conducted in PubMed, Embase, and Cochrane databases up until October 2015. The search strategies included common search strings for diseaserelated and drug-related terms and specific search strings for study design-related terms (Supplementary  Tables 1 and 2 ). The reference lists of citations were also searched for any additional relevant citations.
Study Selection
After duplicate removal, a 2-step process was followed to review the citations identified during the literature searches: (1) preliminary title and abstract assessment, followed by (2) full text review of relevant studies. Selection criteria were developed in the Population, Interventions, Comparators, Outcomes and Study design (PICOS) format 19 and only varied by the type of study design (interventional and non-interventional studies).
The following inclusion criteria were applied for the searches: (1) adult patients diagnosed with IBD; (2) use of a biologic drug (ie, infliximab, adalimumab, certolizumab pegol, golimumab, vedolizumab, natalizumab); (3) assessment of the efficacy (for non-interventional studies: assessment of effectiveness) of treatment on EIMs (ie, musculoskeletal, metabolic bone disease, cutaneous, ocular, hepatobiliary, vascular, hematologic); (4) interventional study or non-interventional study with a minimum of 10 patients receiving the drugs of interest for the management of EIMs; and (5) study published in English language. Conference papers were excluded from the review.
No limits were applied for dates. A complete overview of inclusion and exclusion criteria used for both searches is available in Supplementary Tables 3 and 4 .
Data Extraction
Data from eligible studies were abstracted by using a specifically developed data extraction form. Variables extracted included general study characteristics such as study objectives, study design, inclusion and exclusion criteria or study duration, patients' demographics, and baseline IBD characteristics (including prevalence of EIMs), treatment for IBD and for EIMs, and measures of efficacy and effectiveness of treatment for EIMs.
The methodological quality of the interventional studies included was assessed by using the Centre for Reviews and Dissemination quality assessment criteria for systematic reviews (Supplementary Table 5) . 20 For non-interventional studies, the quality assessment tool developed by the National Institutes of Health 21 was used to assess data quality and evaluate the internal and external validity of the studies (Supplementary Table 6 ).
The significant heterogeneity of designs, populations, and outcomes assessed of the studies included in this systematic review did not allow for data to be meta-analyzed.
Because of the exploratory nature of this systematic review and the significant variability in outcomes measures, grading of evidence identified was not considered.
Results

Efficacy (Interventional Studies)
A flow diagram depicting the findings of the searches and the selection process is provided in Supplementary Figure 1 . A total of 1403 potentially relevant citations were identified through the literature search, and 4 additional citations were identified through manual searches or by reviewing the citations of studies selected. Removal of duplicates followed by review of titles and abstracts and review of full texts yielded 9 relevant studies that fulfilled the eligibility criteria and were extracted.
The efficacy of biologic drugs in the management of EIMs in IBD patients was evaluated in 2 randomized clinical trials and in 7 open label trials. All interventional studies identified in this systematic review were focused on CD patients, with the exception of Brooklyn et al 22 and Kaufman et al, 23 which also included patients with UC. An overview of the main study characteristics and results reported for the selected studies is available in Table 1 .
Randomized clinical trials. Our review included 2 randomized clinical trials. 22, 24 Brooklyn et al 22 assessed the efficacy of infliximab in the treatment of pyoderma gangrenosum in a doubleblind placebo-controlled randomized clinical trial. The study included 30 patients with pyoderma gangrenosum, of whom 13 presented with CD and 6 with UC. The study comprised 2 periods, an initial randomized period of 2 weeks and a subsequent 4-week open label period in which patients received infliximab. The authors reported significant clinical improvement in pyoderma gangrenosum (as per physician and patient global assessment) in a larger proportion of patients receiving infliximab than in those patients receiving placebo at week 2 (46% vs 6%, P ¼ .025). During the subsequent open label period in which all patients received infliximab (N ¼ 29), 69% of patients showed clinical improvement of pyoderma gangrenosum symptoms. 22 A post hoc analysis of the CHARM trial, 24,25 which assessed the efficacy of 2 different regimes of adalimumab (weekly and every other week) vs placebo in 854 CD patients during a period of 56 weeks, showed that the percentage of patients presenting with anemia at end of follow-up was significantly lower among patients in the adalimumab weekly arm (20.7%) or the adalimumab every-other-week arm (25.2%) compared with the placebo arm (31.9%) (P < .05 for both comparisons).
24
Open label trials. The 7 interventional open label trials identified in our search assessed the efficacy of infliximab (n ¼ 4) 23, [26] [27] [28] and adalimumab (n ¼ 3) [29] [30] [31] in EIMs. The studies varied considerably in terms of types of EIMs assessed (several vs specific EIMs), sample size, and study duration. The efficacy of biologic treatment on multiple EIMs was assessed in 4 studies (2 on adalimumab, 2 on infliximab). 23, 26, 29, 30 Favorable results at the end of follow-up period were obtained in all 4 studies, which showed clinical improvement and/or resolution of EIM symptoms in a substantial number of patients.
The CARE study was the largest open label study identified in our search, including 945 CD patients. This was a multicenter phase IIIb trial that assessed the clinical efficacy of adalimumab in patients with moderate to severe CD. The authors reported a reduction in the prevalence of EIMs from baseline to week 20 of treatment. The specific analysis by EIM type showed statistical significance in the difference between baseline and week 20 incidences for the most prevalent EIMs at baseline ( Table 1 ). The global prevalence of EIMs was reduced from 53% (497 of 945 patients) at baseline to 30% at week 20. Of the 497 patients with EIMs at baseline, 79% showed a complete resolution of signs and symptoms of at least 1 EIM at week 20, and 51% were free of EIMs.
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Similar results were reported in the 3 remaining smaller single-center open label studies where treatment efficacy in multiple EIMs was investigated. Barreiro-deAcosta et al 30 assessed the efficacy of adalimumab in 42 CD patients with at least 1 EIM during a period of 6 months. The most common EIMs at baseline were peripheral arthritis (31 patients) and ankylosing spondylitis (7 patients). Partial response or remission at 6 months for these EIMs was reported in 61% and 71% of patients, respectively (Table 1) . Overall, complete remission of the EIM at month 6 was achieved in 38.1% of patients, and an additional 28.5% of patients achieved a clinical partial response. In a short-term study conducted in 23 IBD patients with EIMs (22 CD and 1 UC), a single infusion of infliximab was associated with clinical improvement at week 2 in 64% of patients with arthralgia and inflammatory back pain and in 100% of patients with pyoderma gangrenosum. In addition, arthritis, pyoderma gangrenosum, and aphthous stomatitis were resolved in 25%, 33%, and 100% of patients, respectively (Table 1) . 23 Rispo et al 26 assessed the efficacy of infliximab during a 10-week period in 15 CD patients. The authors reported improvement in the assessment of the ankylosing spondylitis scale (ASAS) (ASAS20 and ASAS40) in 80% and 60% of patients with arthritis, respectively, and complete response in 100% of patients showing arthralgia, cutaneous manifestations, and ocular manifestations. However, in 66% of patients recurrence of EIMs was observed within 8 weeks from the first infusion, and a second course of treatment was administered.
Three additional open label trials report data on the efficacy of anti-TNF treatment for single EIMs. Two trials assessed the efficacy of infliximab in the management of musculoskeletal disease in CD patients, 27,28 and 1 trial evaluated the efficacy of adalimumab in metabolic bone disease.
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Herfarth et al 27 conducted a large 12-week prospective multicenter trial in Germany that included 153 CD patients, of whom 71 showed signs of arthritis or arthralgia at baseline, and 59 had follow-up information and were included in the analysis. Infliximab use was associated with significant improvement of arthritis or arthralgia in 61% of patients (P < .001) and with complete resolution in 46% of patients (Table 1 ). In a long-term cohort study, Generini et al 28 evaluated the efficacy of infliximab in the treatment of 24 patients with (Table 1) . Veerappan et al 31 conducted a 6-month study aimed at exploring the effect of adalimumab on bone metabolism in 20 patients with active CD. The authors reported a significant increase in bone formation markers osteocalcin and procollagen type 1 N-terminal propeptide (P1NP) compared with baseline, but none of the comparisons remained statistically significant at 6 months. They also reported a non-significant decrease in bone resorption marker C-telopeptide of type I collagen (CTx) during a period of 6 months ( Table 1) .
Effectiveness (Non-interventional Studies)
A flow diagram depicting the findings of the searches and the selection process for non-interventional studies is provided in Supplementary Figure 2 . Five hundred thirty-nine relevant citations were identified through the literature search, and 15 additional citations were identified through manual searches or by reviewing the citations of studies selected. Removal of duplicates followed by review of titles and abstracts and review of full texts yielded 13 relevant studies that fulfilled the eligibility criteria and were extracted.
A total of 13 studies were selected for full text review, of which most studies were focused on the effectiveness of biologic treatments in the management of metabolic bone disease in CD patients (n ¼ 6), 32-37 two studies provided evidence on the effectiveness of biologic drugs in the management of anemia, 38, 39 two studies on pyoderma gangrenosum, 40, 41 and two studies on altered hemostasis and coagulation. 42, 43 One additional study provided information on the effectiveness of infliximab in the management of skin and/or joint manifestations in IBD patients. 44 An overview of main study characteristics is available in Table 2 .
The effectiveness of infliximab for metabolic bone disease in CD patients has been assessed in 6 studies. Three cohort studies investigated its long-term effectiveness by evaluating bone mineral density, whereas other 3 prospective short-term cohort studies focused on the assessment of surrogate markers for bone formation or resorption.
Bernstein et al 32 conducted a cohort study to evaluate the effect of 1-year maintenance treatment with infliximab on bone mineral density in 46 CD patients. Patients receiving bisphosphonates were excluded from the study, and 28% and 30% of patients were on corticosteroids and calcium supplementation, respectively. Authors reported statistically significant increases between baseline and year 1 on the bone mineral density of lumbar spine (2.4%), femoral trochanter (2.8%), and femoral neck (2.6%). These gains were not influenced by the presence of osteopenia at baseline, corticosteroid therapy, or calcium supplementation. In a retrospective cohort study, Mauro et al 33 assessed bone mineral density response to infliximab administered every 4-8 weeks by evaluating lumbar bone mass in 15 CD patients and compared it with a control group of CD patients not receiving infliximab (N ¼ 30). The authors reported reductions in the frequencies of osteopenia and osteoporosis from 47% to 33% and from 20% to 7%, respectively, in patients receiving infliximab between both densitometric evaluations (mean interval, 22.6 months). No changes from baseline were observed in the prevalence of osteopenia and osteoporosis (from 10% to 10%) in the control group (Table 2) . Bisphosphonates were used in 20% and 17% of patients in the infliximab group and control group, respectively. Pazianas et al 34 conducted a retrospective cohort study to evaluate the effectiveness of infliximab on bone mineral density in patients with CD and osteopenia or osteoporosis and assessed the effect of concurrent use of bisphosphonates and corticosteroids. Sixty-one patients were included in the study (23 received infliximab, and 36 received bisphosphonates). Among patients not receiving concomitant bisphosphonates, those on infliximab did not show statistically significant differences in the lumbar spine T-score per year compared with those not receiving infliximab. Patients receiving bisphosphonates and infliximab tended to have greater increases in bone mineral density compared with those receiving bisphosphonates only, but the difference did not reach statistical significance (P ¼ .068).
Three additional short-term prospective cohort studies on CD patients reported significant improvements in markers of bone formation such as bone alkaline phosphatase [35] [36] [37] and osteocalcin 36,37 after short-term treatment with infliximab, whereas results for P1NP were variable. 36, 37 The evolution of bone resorption markers was also described in 2 of these studies. Franchimont et al 36 reported that 38.2% of patients showed a predefined relevant clinical improvement in CTx. In the study of Abreu et al, 35 no differences from baseline to week 4 were observed in N-telopeptide of type I collagen.
The effectiveness of anti-TNF therapy in the management of anemia has been assessed in 2 observational studies (a prospective registry and a cross-sectional retrospective study). In a recent prospective singlecenter registry of IBD patients, Koutrobakis et al 38 assessed the long-term effect of anti-TNF therapy on anemia in IBD patients. The registry included 430 IBD patients treated with anti-TNF drugs (infliximab, adalimumab, or certolizumab pegol), of whom 134 presented with anemia at baseline and had a 1-year follow-up period. The prevalence of anemia at year 1 was similar to baseline (36.6% vs 38.1%, P > .05). Hematopoietic response (defined as an increase of hemoglobin !2 g/dL) was observed in 33.6% of patients despite iron replacement therapy that was administered to 94% of patients.
Bergamaschi et al 39 conducted a cross-sectional study to assess the prevalence of anemia in 263 IBD outpatients. Of these, they selected a cohort of 27 CD patients (18 with anemia at baseline) who were treated with infliximab and retrospectively assessed their response at 14 weeks of treatment. For patients with anemia, authors reported hematologic response in 67% (Table 2) . According to authors, hematologic response was already apparent 2 weeks after the first infusion of infliximab. None of these patients had received cyclosporine or methotrexate or received blood transfusions, iron supplementation, or erythropoiesis-stimulating agents.
Two studies assessed the effectiveness of anti-TNF treatment in pyoderma gangrenosum. In a multicenter retrospective cohort study, Argüelles-Arias et al 40 assessed the effectiveness of different treatments including infliximab and adalimumab among others in 67 IBD patients (41 CD, 25 UC, and 2 indeterminate IBD) with pyoderma gangrenosum. A definitive cure was achieved in 22 of 24 patients treated with infliximab (92%) and in all patients (n ¼ 7) treated with adalimumab, with a time to healing ranging between 4 and 8 weeks. In a large case series including 13 patients with IBD (12 CD and 1 UC) and pyoderma gangrenosum, Regueiro et al 41 described that infliximab therapy led to a complete resolution of symptoms in all patients treated after a mean of 86 days (range, 7-210 days) ( Table 2 ).
The effect of infliximab in hemostasis of patients with IBD has been explored in 2 recently published studies. Wang et al 42 conducted a retrospective study on 53 CD patients to assess the influence of infliximab on parameters associated with a hypercoagulation state in patients with CD. Treatment with infliximab was associated with significant reductions of platelet counts (P < .01), mean platelet volume (P < .05), erythrocyte sedimentation rate (P < .01), and C-reactive protein levels (P < .01) at week 14 vs baseline. A single infliximab infusion was also associated with a significant decrease of the levels of fibrinogen (n ¼ 39, P < .001) and D-dimer (n ¼ 25, P ¼ .018) ( Table 2) .
In a prospective cohort study, Bollen et al 43 investigated the effect of infliximab induction therapy on the hemostatic profile of patients with IBD. Patients were classified on the basis of their clinical response to induction treatment with infliximab as primary responders (n ¼ 78) or primary non-responders (n ¼ 13) and analyzed separately. Among primary responders, the hemostatic parameters area under the curve (an integrated measurement reflecting the overall coagulation/ fibrinolysis profile) and amplitude (maximal clot absorbance, indicating clot formation) decreased significantly at the end of the follow-up period (week 14) compared with baseline. In contrast, differences in the levels of hemostatic parameters between baseline and week 14 were not observed for primary non-responders (Table 2) . 
Discussion
Despite the increased interest in the potential use of biologic drugs for the management of EIMs in IBD patients, our systematic review indicates that the number of studies assessing their efficacy or effectiveness for this indication remains limited, especially in UC. However, evidence available from interventional and noninterventional studies suggests that the clinical benefit from infliximab or adalimumab may not be restricted to the local intestinal effect but expand to ameliorate or cure EIMs of IBD including musculoskeletal, mucocutaneous, and ocular manifestations. Evidence also suggests some potential beneficial effect of infliximab and adalimumab therapy on metabolic bone disease and on hematologic or vascular EIMs. In contrast, no or minimal evidence on the efficacy or effectiveness of other biologic drugs considered in our review (ie, certolizumab pegol, golimumab, vedolizumab, natalizumab) was identified.
In general terms, the studies included in our review showed large heterogeneity in designs, including randomized 22 38, 39 or hemostasis, and coagulation alterations. 42, 43 In addition, outcomes measures used to evaluate efficacy and effectiveness of biologic drugs on EIMs varied from study to study. In some cases, variation in the prevalence of specific EIMs from baseline to a certain time point is used, 24, 28, 29, 33, 38 and in other cases clinical improvement or clinical resolution, often considering different definitions for the same EIMs, is reported. 22, 23, 26, 27, 30, 40, 41, 44 Finally, another set of studies use surrogate measures to assess evolution of EIMs. 31, 32, [34] [35] [36] [37] 39, 42, 43 Because of these significant variations, the possibility of meta-analyzing the data was not considered. A summary of efficacy and effectiveness data extracted from selected studies and classified by EIM is available in Supplementary Tables 7  through 25 . This review did not identify any interventional or non-interventional studies specifically assessing the use of biologic drugs for the management of EIMs in UC. In addition, for studies that did not restrict the population to CD patients, the number of UC patients included was either very low 22, 23, 44 or aggregated to CD patients for the reporting of study results. 38, 40, 43 This fact contrasts with a prevalence of EIMs in UC of up to one-third of patients 1 and limits the validity of results available. Future research will be necessary to confirm that the clinical benefit observed replicates in studies including a larger number of UC patients.
The results of this systematic review support the recommendations provided in the recent ECCO consensus document on the use of anti-TNF drugs for the management of EIMs in IBD patients.
14 Both infliximab and adalimumab have proven effective in the management of arthropathy, 23, [26] [27] [28] [29] [30] 44 skin manifestations such as pyoderma gangrenosum 22, 23, 26, 29, 30, 40, 41, 44 or erythema nodosum, 26, 29, 44 and although body of evidence is less robust because of a lower number of patients included, on ocular manifestations such as uveitis. 26, 29, 30 For the remaining EIMs for which evidence has been identified (ie, metabolic bone disease, altered hemostasis, and anemia), some beneficial effect of anti-TNF treatment seems apparent from the results reported, 24,31-39,42,43 although this would need to be confirmed in future studies.
The benefit of anti-TNF therapy in the management of EIMs in IBD seems to be linked with a pathogenic TNF-a dependent mechanism, common to IBD and some EIMs (eg, arthritis, mucocutaneous manifestations such as pyoderma gangrenosum or erythema nodosum, or ocular manifestations including iritis or uveitis). 15 Whether new biologic drugs such as vedolizumab or ustekinumab with different mechanisms of action would show similar benefit on EIMs compared with anti-TNFs currently remains unclear, and data are awaited. Recently published results of a post hoc analysis of the GEMINI 2 study did not show statistically significant benefit of vedolizumab over placebo for the treatment of EIMs in CD. 45 Interestingly, some authors have suggested that IBD patients with EIMs and refractory to anti-TNF treatment may receive vedolizumab as a subsequent treatment line to allow additional mucosal healing, combined with infliximab, to control EIMs. 46 Although the potential economic impact of this innovative combination regimen may pose a significant hurdle for implementation in clinical practice, its efficacy and effectiveness would need to be further explored in new studies.
The interpretation of this systematic review should take into consideration some limitations related to the methodology followed. First, we decided to exclude from our review all studies with less than 10 patients, which reduced the number of studies included in our review by 3 if we consider studies that reached full text review stage only. Because of the low incidence of some of the EIMs in IBD, we cannot discard that some potentially relevant evidence available from case series or small studies was not assessed; however, the evidence provided by this type of studies is relatively weak. In addition, non-English language publications were excluded from this review, and conference abstracts were also not included. Although we acknowledge that some of these decisions may lead to publication bias to some extent, potential impact for the results is expected to be low. There are currently discussions among the scientific community about how and when these limitations should be implemented in systematic reviews. [47] [48] [49] Because of the exploratory nature of our review and the expected variability in the reporting of outcomes measures for efficacy and effectiveness of biologic drugs in EIMs, we did not conduct an assessment of the strength of the body of evidence identified. However, future systematic reviews in the area of EIMs where specific EIMS are targeted would benefit from this approach to facilitate the clinicians' decision-making process.
In summary, EIM management is critical for IBD patients, and an unmet need currently exists. The results of the studies included in our systematic review suggest that infliximab and adalimumab may be effective alternatives for the treatment of certain EIMs associated with IBD including musculoskeletal, cutaneous, and ocular manifestations, and some beneficial effect may be obtained in metabolic bone disease and on hematologic or vascular EIMs. However, the number of studies that have investigated the use of biologic therapy for the treatment of EIMs is relatively low, and the sample sizes are often small to draw any definitive conclusions. This review highlights the need for additional studies that specifically assess the efficacy and effectiveness of biologic drugs in the treatment of EIMs in UC and include a large number of patients.
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